Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

James N. Kochenderfer, Wyndham H. Wilson, John Edward Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric, Mark Raffeld, Debbie Ann N. Nathan, Brock J. Lanier, Richard A. Morgan, Steven A. Rosenberg

Research output: Contribution to journalArticle

685 Citations (Scopus)

Abstract

Adoptive transfer of genetically modified T cells is an attractive approach for generating antitumor immune responses. We treated a patient with advanced follicular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B-cell antigen CD19. The patient's lymphoma underwent a dramatic regression, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti - CD19-CAR-transduced T cells. Blood B cells were absent for at least 39 weeks after anti - CD19-CAR-transduced T-cell infusion despite prompt recovery of other blood cell counts. Consistent with eradication of B-lineage cells, serum immunoglobulins decreased to very low levels after treatment. The prolonged and selective elimination of Blineage cells could not be attributed to the chemotherapy that the patient received and indicated antigen-specific eradication of B-lineage cells. Adoptive transfer of anti - CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326.

Original languageEnglish (US)
Pages (from-to)4099-4102
Number of pages4
JournalBlood
Volume116
Issue number20
DOIs
StatePublished - Nov 18 2010

Fingerprint

CD19 Antigens
T-cells
Antigen Receptors
Lymphoma
T-Cell Antigen Receptor
Cells
T-Lymphocytes
Chemotherapy
Adoptive Transfer
Blood
B-Lymphocytes
Drug Therapy
Follicular Lymphoma
B-Lymphoid Precursor Cells
Blood Cell Count
Immunoglobulins
Bone
Blood Cells
Antigens
Recovery

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., ... Rosenberg, S. A. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood, 116(20), 4099-4102. https://doi.org/10.1182/blood-2010-04-281931

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. / Kochenderfer, James N.; Wilson, Wyndham H.; Janik, John Edward; Dudley, Mark E.; Stetler-Stevenson, Maryalice; Feldman, Steven A.; Maric, Irina; Raffeld, Mark; Nathan, Debbie Ann N.; Lanier, Brock J.; Morgan, Richard A.; Rosenberg, Steven A.

In: Blood, Vol. 116, No. 20, 18.11.2010, p. 4099-4102.

Research output: Contribution to journalArticle

Kochenderfer, JN, Wilson, WH, Janik, JE, Dudley, ME, Stetler-Stevenson, M, Feldman, SA, Maric, I, Raffeld, M, Nathan, DAN, Lanier, BJ, Morgan, RA & Rosenberg, SA 2010, 'Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19', Blood, vol. 116, no. 20, pp. 4099-4102. https://doi.org/10.1182/blood-2010-04-281931
Kochenderfer, James N. ; Wilson, Wyndham H. ; Janik, John Edward ; Dudley, Mark E. ; Stetler-Stevenson, Maryalice ; Feldman, Steven A. ; Maric, Irina ; Raffeld, Mark ; Nathan, Debbie Ann N. ; Lanier, Brock J. ; Morgan, Richard A. ; Rosenberg, Steven A. / Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. In: Blood. 2010 ; Vol. 116, No. 20. pp. 4099-4102.
@article{8e3f957c84014260b99ad6323bedf229,
title = "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19",
abstract = "Adoptive transfer of genetically modified T cells is an attractive approach for generating antitumor immune responses. We treated a patient with advanced follicular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B-cell antigen CD19. The patient's lymphoma underwent a dramatic regression, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti - CD19-CAR-transduced T cells. Blood B cells were absent for at least 39 weeks after anti - CD19-CAR-transduced T-cell infusion despite prompt recovery of other blood cell counts. Consistent with eradication of B-lineage cells, serum immunoglobulins decreased to very low levels after treatment. The prolonged and selective elimination of Blineage cells could not be attributed to the chemotherapy that the patient received and indicated antigen-specific eradication of B-lineage cells. Adoptive transfer of anti - CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326.",
author = "Kochenderfer, {James N.} and Wilson, {Wyndham H.} and Janik, {John Edward} and Dudley, {Mark E.} and Maryalice Stetler-Stevenson and Feldman, {Steven A.} and Irina Maric and Mark Raffeld and Nathan, {Debbie Ann N.} and Lanier, {Brock J.} and Morgan, {Richard A.} and Rosenberg, {Steven A.}",
year = "2010",
month = "11",
day = "18",
doi = "10.1182/blood-2010-04-281931",
language = "English (US)",
volume = "116",
pages = "4099--4102",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

AU - Kochenderfer, James N.

AU - Wilson, Wyndham H.

AU - Janik, John Edward

AU - Dudley, Mark E.

AU - Stetler-Stevenson, Maryalice

AU - Feldman, Steven A.

AU - Maric, Irina

AU - Raffeld, Mark

AU - Nathan, Debbie Ann N.

AU - Lanier, Brock J.

AU - Morgan, Richard A.

AU - Rosenberg, Steven A.

PY - 2010/11/18

Y1 - 2010/11/18

N2 - Adoptive transfer of genetically modified T cells is an attractive approach for generating antitumor immune responses. We treated a patient with advanced follicular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B-cell antigen CD19. The patient's lymphoma underwent a dramatic regression, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti - CD19-CAR-transduced T cells. Blood B cells were absent for at least 39 weeks after anti - CD19-CAR-transduced T-cell infusion despite prompt recovery of other blood cell counts. Consistent with eradication of B-lineage cells, serum immunoglobulins decreased to very low levels after treatment. The prolonged and selective elimination of Blineage cells could not be attributed to the chemotherapy that the patient received and indicated antigen-specific eradication of B-lineage cells. Adoptive transfer of anti - CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326.

AB - Adoptive transfer of genetically modified T cells is an attractive approach for generating antitumor immune responses. We treated a patient with advanced follicular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B-cell antigen CD19. The patient's lymphoma underwent a dramatic regression, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti - CD19-CAR-transduced T cells. Blood B cells were absent for at least 39 weeks after anti - CD19-CAR-transduced T-cell infusion despite prompt recovery of other blood cell counts. Consistent with eradication of B-lineage cells, serum immunoglobulins decreased to very low levels after treatment. The prolonged and selective elimination of Blineage cells could not be attributed to the chemotherapy that the patient received and indicated antigen-specific eradication of B-lineage cells. Adoptive transfer of anti - CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326.

UR - http://www.scopus.com/inward/record.url?scp=78549278144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549278144&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-04-281931

DO - 10.1182/blood-2010-04-281931

M3 - Article

C2 - 20668228

AN - SCOPUS:78549278144

VL - 116

SP - 4099

EP - 4102

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -